PepGen Inc. announced the appointment of Habib Joseph Dable to its Board of Directors. Mr. Dable is the former President and Chief Executive Officer of Acceleron Pharma, and brings nearly three decades of experience working with emerging biotech and big pharma companies. As President and Chief Executive Officer of Acceleron Pharma, Mr. Dable guided Acceleron to a new stage of growth and shareholder value, leading to Acceleron's first blockbuster launch in 2019 and eventual sale to Merck & Co.

in 2021 for over $11 billion. Prior to his role at Acceleron, Mr. Dable worked at Bayer AG where, over the course of his 22-year tenure, he served in roles of increasing responsibility, including Global Head, Neurology and Ophthalmology and President of U.S. Pharmaceuticals. During this time, Mr. Dable led the launch of various blockbuster brands, including EYLEA®, Stivarga®, and Xofigo®.

Mr. Dable is also a former Independent Director of Millendo Therapeutics and previously served on the Board of Directors of the Biotechnology Innovation Organization (BIO). He currently serves as an Independent Director at Blueprint Medicines and Albireo Pharma, and is a part-time Venture Partner at RA Capital Management. Mr. Dable received a bachelor's degree in Business Administration and an MBA from the University of New Brunswick.